Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Luminex Will Be Acquired By DiaSorin For About $1.8Bn

Executive Summary

The buyout will broaden DiaSorin’s positioning in the fast-growing molecular diagnostics space and expand Luminex’s foothold outside the US.

You may also be interested in...



DiaSorin Completes $1.8bn Acquisition Of Luminex

The brokered deal will broaden DiaSorin’s offerings in the rapidly growing liquid diagnostics market, while also providing Luminex furthered access to markets outside of the US.

COVID-19: Nanomix Wins BARDA Funding For Mobile Point-Of-Care Assay

The US government’s Biomedical Advanced Research and Development Authority has awarded Nanomix up to $570,000 to develop a SARS-CoV-2 test for its portable, rapid Nanomix eLab analyzer.

Behavioral Health Company Two Chairs Secures $72M In Equity And Debt Infusion

Two Chairs, which uses algorithms to match the right therapists with patients, secured $72m in investment to expand its business.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT143780

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel